AM 365

Drug Profile

AM 365

Latest Information Update: 14 Aug 2002

Price : $50

At a glance

  • Originator Zenyth Therapeutics
  • Class Antivirals; Nucleosides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 11 Jul 2002 Discontinued - Phase-II for Hepatitis B in Australia (unspecified route)
  • 22 Mar 2001 Phase-II clinical trials for Hepatitis B in Australia (Unknown route)
  • 05 Oct 2000 Phase I trials have been completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top